Literature DB >> 6289317

IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells.

D Herlyn, H Koprowski.   

Abstract

Monoclonal antibodies of IgG2a isotype specifically inhibited growth of human tumors in nude mice. Twenty-three monoclonal antibodies of other isotypes showed no tumoricidal reactivity. Complement depletion of nude mice had no effect on tumor suppression by monoclonal antibody. The role of T and killer cells as mediators of the monoclonal antibody effect in nude mice was virtually excluded. On the other hand, macrophages were strongly incriminated as effector cells because silica treatment of nude mice abolished the tumoricidal effect of monoclonal antibody. IgG2a monoclonal antibody-dependent macrophage-mediated cytotoxicity assays with human tumor cells in culture resulted in specific lysis of tumor cells.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6289317      PMCID: PMC346757          DOI: 10.1073/pnas.79.15.4761

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  22 in total

1.  Cytolytic and cytostatic activity on tumor cells of circulating human monocytes.

Authors:  A Mantovani; T R Jerrells; J H Dean; R B Herberman
Journal:  Int J Cancer       Date:  1979-01-15       Impact factor: 7.396

2.  Antigenic differences between alveolar and peritoneal macrophages of the rat. Lack of population-specific determinants.

Authors:  G Boltz-Nitulescu; O Foerster
Journal:  Immunology       Date:  1979-11       Impact factor: 7.397

3.  Enhancement by interferon of natural killer cell activity in mice.

Authors:  A Senik; I Gresser; C Maury; M Gidlund; A Orn; H Wigzell
Journal:  Cell Immunol       Date:  1979-04       Impact factor: 4.868

4.  Rapid identification of monocytes in a mixed mononuclear cell preparation.

Authors:  S B Tucker; R V Pierre; R E Jordon
Journal:  J Immunol Methods       Date:  1977       Impact factor: 2.303

5.  The effect of particle size on the immunodepressive properties of silica.

Authors:  J J Wirth; W P Carney; E F Wheelock
Journal:  J Immunol Methods       Date:  1980       Impact factor: 2.303

6.  Acute viral infection: tissue injury mediated by anti-viral antibody through a complement effector system.

Authors:  M B Oldstone; F J Dixon
Journal:  J Immunol       Date:  1971-11       Impact factor: 5.422

7.  Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies.

Authors:  M Herlyn; Z Steplewski; D Herlyn; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1979-03       Impact factor: 11.205

8.  Monoclonal antibodies in cell-mediated cytotoxicity against human melanoma and colorectal carcinoma.

Authors:  D Herlyn; M Herlyn; Z Steplewski; H Koprowski
Journal:  Eur J Immunol       Date:  1979-08       Impact factor: 5.532

9.  Mouse leukemia: therapy with monoclonal antibodies against a thymus differentiation antigen.

Authors:  I D Bernstein; M R Tam; R C Nowinski
Journal:  Science       Date:  1980-01-04       Impact factor: 47.728

10.  Study of antibodies against human melanoma produced by somatic cell hybrids.

Authors:  H Koprowski; Z Steplewski; D Herlyn; M Herlyn
Journal:  Proc Natl Acad Sci U S A       Date:  1978-07       Impact factor: 11.205

View more
  82 in total

Review 1.  Recombinant antibodies for the diagnosis and treatment of cancer.

Authors:  Jürgen Krauss
Journal:  Mol Biotechnol       Date:  2003-09       Impact factor: 2.695

2.  Biological activity in the human system of isotype variants of oligosaccharide-Y-specific murine monoclonal antibodies.

Authors:  D Scholz; M Lubeck; H Loibner; J McDonald-Smith; Y Kimoto; H Koprowski; Z Steplewski
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

3.  Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells.

Authors:  M A Ghetie; E M Podar; A Ilgen; B E Gordon; J W Uhr; E S Vitetta
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-08       Impact factor: 11.205

4.  Plant-derived anti-Lewis Y mAb exhibits biological activities for efficient immunotherapy against human cancer cells.

Authors:  Robert Brodzik; Magdalena Glogowska; Katarzyna Bandurska; Monika Okulicz; Deepali Deka; Kisung Ko; Joke van der Linden; Jeanette H W Leusen; Natalia Pogrebnyak; Maxim Golovkin; Zenon Steplewski; Hilary Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-23       Impact factor: 11.205

5.  A monoclonal antibody to human immunodeficiency virus type 1 which mediates cellular cytotoxicity and neutralization.

Authors:  P A Broliden; K Ljunggren; J Hinkula; E Norrby; L Akerblom; B Wahren
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

6.  Immunohistochemical monitoring of metastatic colorectal carcinoma in patients treated with monoclonal antibodies (MAb 17-1A).

Authors:  J Shetye; J E Frödin; B Christensson; C Grant; B Jacobsson; S Sundelius; M Sylvén; P Biberfeld; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

7.  Ablation of human colon carcinoma in nude mice by 131I-labeled monoclonal anti-carcinoembryonic antigen antibody F(ab')2 fragments.

Authors:  F Buchegger; C Pfister; K Fournier; F Prevel; M Schreyer; S Carrel; J P Mach
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

8.  Acute antibody-mediated rejection of skin grafts without involvement of granulocytes or complement.

Authors:  M J Bogman; I M Cornelissen; R A Koene
Journal:  Am J Pathol       Date:  1984-05       Impact factor: 4.307

9.  Monoclonal antibody-directed effector cells selectively lyse human melanoma cells in vitro and in vivo.

Authors:  G Schulz; T F Bumol; R A Reisfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205

10.  Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma.

Authors:  M Naramura; S D Gillies; J Mendelsohn; R A Reisfeld; B M Mueller
Journal:  Cancer Immunol Immunother       Date:  1993-10       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.